Updating results

1010 results

Sort: Relevance | Date

Diabetic foot problems: prevention and management (NG19)

This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

NICE guideline Published August 2015 Last updated October 2019

Leg ulcer infection: antimicrobial prescribing (NG152)

This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published February 2020

Prostatitis (acute): antimicrobial prescribing (NG110)

This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Pyelonephritis (acute): antimicrobial prescribing (NG111)

This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Cellulitis and erysipelas: antimicrobial prescribing (NG141)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Pneumonia (community-acquired): antimicrobial prescribing (NG138)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Sore throat (acute): antimicrobial prescribing (NG84)

This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

Antimicrobial prescribing guideline Published January 2018

Sinusitis (acute): antimicrobial prescribing (NG79)

This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

Antimicrobial prescribing guideline Published October 2017

Cough (acute): antimicrobial prescribing (NG120)

This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published February 2019

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published December 2018

Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published December 2018

Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)

This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published November 2018

Otitis media (acute): antimicrobial prescribing (NG91)

This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.

Antimicrobial prescribing guideline Published March 2018

Urinary tract infection (lower): antimicrobial prescribing (NG109)

This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published October 2018

Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of hospital-acquired pneumonia. It does not cover ventilator-associated pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Antimicrobial prescribing guideline Published September 2019

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Highly specialised technologies guidance Published October 2019

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Highly specialised technologies guidance Published November 2019

Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa in adults and children

Highly specialised technologies guidance Published December 2015

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

Highly specialised technologies guidance Published July 2016

Migalastat for treating Fabry disease (HST4)

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Highly specialised technologies guidance Published February 2017

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

Highly specialised technologies guidance Published January 2015

Eliglustat for treating type 1 Gaucher disease (HST5)

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Highly specialised technologies guidance Published June 2017

Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Highly specialised technologies guidance Published August 2017

Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

Highly specialised technologies guidance Published February 2018

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Highly specialised technologies guidance Published October 2018

Inotersen for treating hereditary transthyretin amyloidosis (HST9)

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Highly specialised technologies guidance Published May 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)

Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation (AF)

Interventional procedures guidance Published April 2006

Holmium laser prostatectomy (IPG17)

Evidence-based recommendations on holmium laser prostatectomy (removal of the prostate) for treating Benign prostatic obstruction (BPO)

Interventional procedures guidance Published November 2003

Living-donor lung transplantation for end-stage lung disease (IPG170)

Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease

Interventional procedures guidance Published May 2006

Laparoscopic helium plasma coagulation for the treatment of endometriosis (IPG171)

Evidence-based recommendations on laparoscopic helium plasma coagulation (plasma beam) for treating endometriosis

Interventional procedures guidance Published May 2006

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184)

Evidence-based recommendations on high-intensity focused ultrasound for atrial fibrillation (AF) in association with other cardiac surgery

Interventional procedures guidance Published July 2006

Tonsillectomy using laser (IPG186)

Evidence-based recommendations on tonsillectomy (removing tonsils) using laser to cut tonsils and seal blood vessels

Interventional procedures guidance Published July 2006

Catheterless oesophageal pH monitoring (IPG187)

Evidence-based recommendations on catheterless oesophageal pH monitoring (placing small wireless capsule in gullet to check the level of acid)

Interventional procedures guidance Published July 2006

Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)

Evidence-based recommendations on deep brain stimulation (permanent electrodes planted in brain) for tremor and dystonia (excluding Parkinson's disease)

Interventional procedures guidance Published August 2006

Deep brain stimulation for Parkinson's disease (IPG19)

Evidence-based recommendations on deep brain stimulation (DBS) to treat symptoms of Parkinson's disease (PD)

Interventional procedures guidance Published November 2003

Stimulated graciloplasty for faecal incontinence (IPG159)

Evidence-based recommendations on stimulated graciloplasty for faecal incontinence (creating a new anal sphincter muscle)

Interventional procedures guidance Published March 2006

High dose rate brachytherapy for carcinoma of the cervix (IPG160)

Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix (cervical cancer)

Interventional procedures guidance Published March 2006

Percutaneous endoscopic colostomy (IPG161)

Evidence-based recommendations on percutaneous endoscopic colostomy (PEC)

Interventional procedures guidance Published March 2006

Endoscopic dacryocystorhinostomy (IPG113)

Evidence-based recommendations on endoscopic dacryocystorhinostomy (DCR) for treating lacrimal sac or nasolacrimal duct obstruction (NLDO)

Interventional procedures guidance Published February 2005

Lung volume reduction surgery for advanced emphysema (IPG114)

Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema

Interventional procedures guidance Published February 2005

High-intensity focused ultrasound for prostate cancer (IPG118)

Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer

Interventional procedures guidance Published March 2005

Photodynamic therapy for bile duct cancer (IPG134)

Evidence-based recommendations on photodynamic therapy for bile duct cancer

Interventional procedures guidance Published July 2005

Laparoscopic liver resection (IPG135)

Evidence-based recommendations on laparoscopic liver resection (keyhole removal of hepatocellular carcinoma [HCC] and for benign tumours and cysts)

Interventional procedures guidance Published July 2005

Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)

Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy; keyhole surgery to remove a kidney)

Interventional procedures guidance Published August 2005

High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer (IPG174)

Evidence-based recommendations on high dose rate (HDR) brachytherapy in combination with external-beam radiotherapy (EBRT) for localised prostate cancer

Interventional procedures guidance Published May 2006

Percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum (IPG176)

Evidence-based recommendations on percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum (PAIVS)

Interventional procedures guidance Published May 2006

Foker technique for long-gap oesophageal atresia (IPG153)

Evidence-based recommendations on the Foker technique for long-gap oesophageal atresia (OA/TOF)

Interventional procedures guidance Published January 2006

Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)

Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions)

Interventional procedures guidance Published February 2006